News


ExpreS2ion is looking for a Sales Manager

ExpreS2ion Biotechnologies is looking for a Sales Manager with biotechnology field international selling experience for our office in Horsholm, Denmark. See and follow instructions in this job description: Sales Manager Profile


ExpreS2ion’s CSO Dr. Wian de Jongh to speak at the ISBiotech 8th Spring Meeting in Norfolk, Virginia, USA – March 5-7

ExpreS2ion Biotechnologies will be presenting at the ISBiotech 8th Spring Meeting taking place on March 5-7, 2018 in Norfolk, Virginia, USA. The presentation is titled “HER2 Cancer Vaccine Optimization by Combining Drosophila S2 Insect Cell Manufacturing with a Novel VLP-Display Technology”. The speaker is Dr. Wian de Jongh, CSO, ExpreS2ion…


Upcoming Webinar: Developing an anti-HER2 breast cancer vaccine using advantageous Drosophila S2 cell protein expression and virus-like -particle display technologies

ExpreS2ion Biotechnologies and AdaptVac will be presenting at the free webinar on March 14 at 5PM CET / 4PM GMT / 12PM EDT / 9AM PDT, hosted by the leading science journal published by Elsevier, Vaccine. The webinar is titled “Developing a HER2-VLP vaccine for treatment of HER2-positive cancer; optimizing…


Media article about ExpreS2ion in Affärstidningen Näringsliv, a journal about Life Science in Greater Copenhagen

Expres2ion Biotechnologies is mentioned in the Swedish newspaper Affärstidningen Näringsliv, in the supplement section “Time to Unite – a Greater Medicon Valley”. The article with the headline “Using insect cells in biotechnology for better protein production” can be seen on page 13 on the link to the interactive web version…


Media article about ExpreS2ion in MedWatch, a Danish business journal about the Life Sciences industry

ExpreS2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “ExpreS2ion-direktør efter første fulde regnskabsår: “Vi står i en unik position til at ekspandere” ”. he article includes an interview with CEO Steen Klysner. The article can be seen on https://medwatch.dk/secure/Medicinal___Biotek/article10287938.ece


ExpreS2ion Biotechnologies Announces Research License Agreement with the University of Pennsylvania

Horsholm, Denmark, November 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that University of Pennsylvania, Philadelphia, USA, has signed a Research License Agreement granting University of Pennsylvania the right to conduct research using ExpreS2ion’s proprietary protein expression system, ExpreS2. The…


The Francis Crick Institute Renews the Research License Agreement with ExpreS2ion Biotechnologies

Horsholm, Denmark, June 26, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the Francis Crick Institute, London, United Kingdom, has agreed to amend the Research License Agreement about ExpreS2ion’s proprietary ExpreS2 expression system for another year. The Research License Agreement…


“Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies”

The ExpreS2 system was used for the production of recombinant PvDBP_RII (SalI) protein for ELISA-based assays in the article “Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies” Abstract BACKGROUND. Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by…